SLU-PP-332 – ERR Agonist

Description

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptor (ERR) family of nuclear receptors, with primary activity reported toward ERRα while also demonstrating activity at ERRβ and ERRγ in preclinical studies. SLU-PP-332 has emerged as a promising research tool for investigating cellular energy metabolism, mitochondrial biology, skeletal muscle physiology, and exercise-mimetic signaling.

Unlike classical estrogen receptors, estrogen-related receptors are orphan nuclear receptors that regulate genes involved in mitochondrial function, oxidative metabolism, fatty acid utilization, and cellular energy homeostasis. SLU-PP-332 has been shown to activate ERR-dependent transcriptional programs, leading to increased expression of genes associated with mitochondrial biogenesis, oxidative phosphorylation, and metabolic adaptation. Many of these molecular responses resemble those normally observed following endurance exercise.

One of the principal downstream pathways associated with SLU-PP-332 is the induction of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1 alpha), a master regulator of mitochondrial biogenesis. Experimental studies have also reported modulation of DDIT4, SIRT1, and NOX4, suggesting coordinated effects on cellular stress responses, mitochondrial respiration, oxidative stress regulation, and energy metabolism. Preclinical research has explored the potential of SLU-PP-332 in models of obesity, insulin resistance, skeletal muscle adaptation, aging, and heart failure.

Product Information

✅ Each bottle contains 60 capsules
✅ Each capsule provides 200 mcg of SLU-PP-332
✅ A potent ERR agonist that mimics exercise-induced metabolic benefits

What Is It Used For and Its Purpose 

SLU-PP-332 is primarily utilized as a research tool for investigating the molecular mechanisms that regulate cellular energy metabolism and exercise adaptation. By activating estrogen-related receptors, particularly ERRα, researchers can study transcriptional programs that control mitochondrial biogenesis, oxidative phosphorylation, lipid utilization, and skeletal muscle remodeling.

The compound has attracted attention because it reproduces several molecular responses typically induced by endurance exercise without requiring increased physical activity. This has made SLU-PP-332 valuable for studying exercise physiology, metabolic disease mechanisms, age-related muscle dysfunction, and mitochondrial biology in experimental systems.

Current investigations focus on how ERR activation influences metabolic flexibility, fatty acid oxidation, glucose homeostasis, oxidative stress responses, and cardiovascular energetics.

Research Applications

• Endocrinology
• Metabolism research
• Exercise physiology
• Mitochondrial biology
• Nuclear receptor signaling
• ERRα/ERRβ/ERRγ signaling
• Skeletal muscle biology
• Adipose tissue biology
• Lipid metabolism
• Insulin signaling
• Obesity research
• Aging research
• Oxidative stress research
• Cardiovascular physiology

Potential Scientific Benefits

Preclinical evidence indicates that SLU-PP-332 activates transcriptional networks associated with mitochondrial metabolism and oxidative energy production. Studies have demonstrated activation of ERR-dependent gene expression, including increased PGC-1α signaling, which is widely recognized as a central regulator of mitochondrial biogenesis and oxidative metabolism.

Studies have also reported increased energy expenditure, enhanced fatty acid oxidation, improved insulin sensitivity, reductions in hepatic lipid accumulation, and decreased body weight in models of diet-induced obesity. Experimental findings have also demonstrated improved exercise endurance and increased oxidative skeletal muscle fiber characteristics, consistent with activation of aerobic metabolic pathways.

Additional investigations suggest that SLU-PP-332 influences cellular stress responses through upregulation of DDIT4 and SIRT1 while reducing expression of NOX4, an enzyme involved in reactive oxygen species generation. These molecular changes may contribute to reduced oxidative stress and improved mitochondrial function observed in experimental models, although causal relationships continue to be investigated.

Emerging research has also explored the compound in experimental models of age-related muscle atrophy and heart failure. Preclinical findings suggest improvements in mitochondrial metabolism, muscle function, and cardiac energy utilization. Because SLU-PP-332 exhibits activity at multiple ERR isoforms, experimental studies have raised theoretical concerns regarding prolonged activation of ERRβ and ERRγ signaling, including the potential for cardiac hypertrophic responses observed in some preclinical models. Extended treatment has also been associated with altered glycogen storage in skeletal muscle, highlighting the importance of further long-term safety evaluation.

Reported Biological Findings in Research

• Activation of ERRα-dependent transcription
• Stimulation of PGC-1α-mediated mitochondrial biogenesis
• Upregulation of DDIT4 expression
• Increased SIRT1 expression
• Downregulation of NOX4-associated oxidative stress pathways
• Enhanced mitochondrial oxidative metabolism
• Increased fatty acid oxidation
• Modulation of lipid metabolism
• Improved insulin sensitivity in animal models
• Increased exercise endurance in preclinical studies
• Reduced hepatic triglyceride accumulation in experimental obesity models
• Investigation of skeletal muscle remodeling and oxidative fiber adaptation
• Evaluation in heart failure and age-related muscle atrophy models

Current scientific evidence remains limited, and further well-controlled clinical studies are required to establish long-term efficacy and safety in humans.

Research Data Sheet

The following summarizes the currently available research information for SLU-PP-332.

• Compound / Peptide Name: SLU-PP-332
• Sequence: Not applicable
• Classification: Synthetic small-molecule ERR agonist
• Molecular Formula: C₁₈H₁₄N₂O₂
• Molecular Weight: 290.3 g/mol
• CAS Number: 303760-60-3
• Form: Solid
• Appearance: White to off-white
• Storage: Refrigerate at 2–8°C; long-term storage at −20°C
• Research Categories: Metabolism, Exercise Physiology, Mitochondrial Biology, Nuclear Receptor Signaling, Obesity Research, Aging Research, Skeletal Muscle Biology, Cardiovascular Physiology, Oxidative Stress Research

Safety Precautions

SLU-PP-332 is an investigational research compound intended exclusively for laboratory research by qualified personnel. It has not been approved for therapeutic or clinical use, and comprehensive human safety data remain unavailable. Appropriate laboratory procedures should be followed during storage, handling, preparation, and disposal.

• Research use only
• Not for human consumption
• Not intended to diagnose, treat, or prevent disease
• Wear appropriate personal protective equipment (gloves, laboratory coat, and eye protection)
• Follow aseptic handling procedures where applicable
• Store under recommended refrigerated conditions
• Avoid repeated freeze–thaw cycles if prepared in solution
• Maintain appropriate labeling and laboratory documentation
• Dispose of waste in accordance with institutional and local regulations
• Human safety data remain limited
• Long-term biological effects have not been fully characterized

Conclusion

SLU-PP-332 represents a novel synthetic agonist of estrogen-related receptors that has rapidly become an important research tool for investigating the molecular biology of energy metabolism and exercise adaptation. By activating ERR-dependent transcriptional networks, the compound provides researchers with a means of studying mitochondrial biogenesis, oxidative metabolism, lipid utilization, and skeletal muscle physiology in experimental settings.

Current studies suggest that SLU-PP-332 influences multiple biological pathways associated with metabolic homeostasis, including PGC-1α signaling, SIRT1 regulation, oxidative stress responses, fatty acid oxidation, and mitochondrial function. These observations have generated significant interest in its application to obesity, insulin resistance, aging, cardiovascular physiology, and exercise-mimetic research.

As an investigational molecule, SLU-PP-332 should be used exclusively within appropriately controlled research environments to further characterize its biological mechanisms and potential applications in metabolic and translational biomedical research.